We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. An updated algorithm for the Omnipod 5 automated insulin ...

Insulet is bringing a splash of color to the diabetes technology market. Working with Pantone, the insulin pump company has created the “bright and joyful tropical orange yellow” color Omnipod Mango.

ACTON, Mass. - Insulet Corporation (NASDAQ:PODD), a $22.7 billion medical device company with impressive 26% year-over-year revenue growth, has partnered with Pantone to create "Omnipod Mango," a new ...

Insulet Corporation (NASDAQ:PODD) reported second-quarter adjusted earnings of $1.17 per share, beating the consensus of 92 cents. PODD shares are rallying today. Track live prices here. The automated ...

Approximately 300,000 Canadians have type 1 diabetes, with the number of cases growing at an estimated 4.4% per year 2 The Omnipod 5 System is designed to be customer-centric and aims to deliver ...

The em dash (—) is a supremely useful (and fashionable) piece of punctuation used in writing and editing, often in place of a comma, colon, or parenthesis. While you might want to utilize it to make ...

OKLAHOMA CITY — Medicaid recipients in Oklahoma who have diabetes may benefit from a proposed change in the way the state covers costs of automated insulin management systems. On Monday, lawmakers on ...

Expanded indication makes Omnipod the first automated insulin delivery system to be approved for the management of both type 1 and type 2 diabetes. The FDA has cleared Insulet Corporation’s Omnipod 5 ...

The US Food and Drug Administration (FDA) has cleared the Omnipod 5 for use by people aged 18 and older with type 2 diabetes, a first for any automated insulin delivery (AID) system. The Omnipod 5 ...

Insulet (NASDAQ:PODD) announced Friday that its tubeless insulin delivery system, Omnipod 5, performed better than conventional insulin pumps in a clinical trial for patients with type 1 diabetes. Its ...

Insulet PODD appears well-positioned on solid prospects in the diabetes market. The company is progressing well with respect to product innovation and geographic expansion. The stock carries a Zacks ...